STX vs. ELX, TAO, APC, DGI, IDEA, BXP, ANCR, VLG, EAH, and DNL
Should you be buying Shield Therapeutics stock or one of its competitors? The main competitors of Shield Therapeutics include El Oro (ELX), TAO Alpha (TAO), Apc Technology Group (APC), DG Innovate (DGI), Ideagen (IDEA), Beximco Pharmaceuticals (BXP), Animalcare Group (ANCR), Venture Life Group (VLG), ECO Animal Health Group (EAH), and Diurnal Group (DNL).
Shield Therapeutics vs. Its Competitors
El Oro (LON:ELX) and Shield Therapeutics (LON:STX) are both small-cap computer hardware companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.
In the previous week, Shield Therapeutics had 5 more articles in the media than El Oro. MarketBeat recorded 5 mentions for Shield Therapeutics and 0 mentions for El Oro. Shield Therapeutics' average media sentiment score of 0.24 beat El Oro's score of -1.05 indicating that Shield Therapeutics is being referred to more favorably in the news media.
6.7% of Shield Therapeutics shares are owned by institutional investors. 3.1% of Shield Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Shield Therapeutics has a consensus target price of GBX 15, indicating a potential upside of 91.69%. Given Shield Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Shield Therapeutics is more favorable than El Oro.
El Oro has a net margin of 0.00% compared to Shield Therapeutics' net margin of -173.43%. El Oro's return on equity of 0.00% beat Shield Therapeutics' return on equity.
El Oro has higher earnings, but lower revenue than Shield Therapeutics. Shield Therapeutics is trading at a lower price-to-earnings ratio than El Oro, indicating that it is currently the more affordable of the two stocks.
Summary
Shield Therapeutics beats El Oro on 9 of the 13 factors compared between the two stocks.
Get Shield Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for STX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding STX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Shield Therapeutics Competitors List
Related Companies and Tools
This page (LON:STX) was last updated on 9/17/2025 by MarketBeat.com Staff
Free STX Stock Alerts